Cancer diagnostics using blood samples
A normal blood draw is enough to help your doctor detect and classify suspected or diagnosed cancer at various stages of the disease.
Our servicesHow does it work?
If you already have a cancer diagnosis, you and your treating physician should agree that iCellate's service OncoMate® is right for you.
GeneMate® and CellMate® do not require prior physician consultation.
Our services
Inherited cancer risk
Cancer in the family can cause great, and sometimes unnecessary, concern. iCellate analyzes the DNA in a simple saliva sample, assesses your hereditary risk for cancer, and suggests preventative action.
Genetic cancer evaluation
iCellate’s genetic cancer evaluation, using circulating tumor DNA (ctDNA), provides detailed genetic tumor information which may reveal targeted treatment options.
Personal cancer screening
Early detection is important for effective cancer treatment. iCellate can, even before symptoms occur, detect the spreading cancer cells through a simple blood test.
What answers can iCellate give?
Inherited cancer risk
Cancer originates from gene mutations in cells. Exposures or habits such as smoking or poor eating habits are well-known risk factors. Mutations may also be inherited.
Of all cancer diagnoses, about 5-10% are hereditary. The risk of developing cancer may be reduced if you take action in time.
If several people in your family have had cancer, especially at an early age, you may want to assess your risk level through our inherited cancer test.
Genetic cancer evaluation
iCellate’s blood biopsies complement the established methods in general healthcare. These new methods are not yet standard in today’s medical care.
iCellate is commited to providing patients with the best possible care through continuous iteration, enhancement and validation of its services.
Notable awards and grants
CellMate®
iCellate awarded Horizon 2020 grant to enable launch of CellMate® in the European market in collaboration with QIAGEN and UKSH.
Comp. diagnostics
Together with the Swiss pharmaceutical company Elthera, iCellate received Eurostars to develop a companion diagnostic in pancreatic cancer.
R&D Collaboration
iCellate entered strategic partnerships with some key affiliates, leading to new discoveries in cell detection automation and the service CellMate®.
Verification
iCellate was awarded the ”Vinn verifiering” by Vinnova that resulted in early verification of the CTC isolation technique.